GlassScriptPhysician profile
Andrew E Holzman
NPI 1003085093
$4,738.10
in general payments reported to CMS, 2019-2025
14 companies · $1,082 in 2025
The $1,082 reported for 2025 was more than what 79% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $272 · 2020: $517 · 2021: $625 · 2022: $709 · 2023: $911 · 2024: $621 · 2025: $1,082.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,614.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,614.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,800.38 | 2019-2025 | Wavelight Refractive Suite, Wavelight Sightmap, Wavelight Ex500 Excimer Laser |
| Glaukos Corporation | $1,078.35 | 2021-2025 | Photrexa Viscous and Photrexa, Kxl1b-Ce-Marked Kxlsystem, Kxl System (Not Refurbished) |
| Kala Pharmaceuticals, INC. | $675.14 | 2019-2022 | |
| Harrow Eye, LLC | $248.41 | 2024-2025 | Vevye |
| Sun Pharmaceutical Industries INC. | $192.50 | 2020-2022 | |
| Bausch & Lomb Americas INC. | $125.03 | 2023-2025 | Xiidra, Miebo |
| Oyster Point Pharma, INC. | $119.39 | 2022-2024 | Tyrvaya, Ryzumvi |
| Eyevance Pharmaceuticals LLC | $103.93 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $103.27 | 2019-2022 | |
| Dompe US, INC. | $102.24 | 2024-2025 | Oxervate |
| Allergan, INC. | $82.09 | 2020-2021 | |
| Rxsight INC | $36.57 | 2024 | Light Adjustable Lens (Lal), Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd) |
| Tarsus Pharmaceuticals, INC. | $36.35 | 2024 | Xdemvy |
| Carl Zeiss Meditec USA, INC. | $34.45 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Holzman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.